Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions

Nature Medicine

Volumn 7, Issue 5, 2001, Pages 575-583

  Carmeliet, Peter ^a   Moons, Lieve ^a   Luttun, Aernout ^a   Vincenti, Valeria ^b   Compernolle, Veerle ^a   De Mol, Maria ^a   Wu, Yan ^c   Bono, Françoise ^d   Devy, Laetitia ^e   Beck, Heike ^f   Scholz, Dimitri ^g   Acker, Till ^f   Dipalma, Tina ^b   Dewerchin, Mieke ^a   Noel, Agnes ^e   Stalmans, Ingeborg ^a   Barra, Adriano ^b   Blacher, Sylvia ^e   Vandendriessche, Thierry ^a   Ponten, Annica ⁱ   Eriksson, Ulf ⁱ   Plate, Karl H ^f   Foidart, Jean Michel ^e   Schaper, Wolfgang ^g   Charnock Jones, D Stephen ^h   Hicklin, Daniel J ^c   Herbert, Jean Marc ^d   Collen, Désiré ^a   Persico, M Graziella ^b   more..

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^c ELI LILLY AND COMPANY   (United States)

^d SANOFI   (France)

^e UNIVERSITY OF LIÈGE   (Belgium)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^g MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRAVASATION; GENE DISRUPTION; HISTOPATHOLOGY; LIGAND BINDING; MEMBRANE BINDING; MOUSE; NONHUMAN; PLACENTA DEVELOPMENT; PRIORITY JOURNAL; RECEPTOR UPREGULATION; WOUND HEALING;

ANIMALS; BASE SEQUENCE; CAPILLARY PERMEABILITY; DNA PRIMERS; EMBRYONIC AND FETAL DEVELOPMENT; ENDOTHELIAL GROWTH FACTORS; LYMPHOKINES; MICE; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PLASMA; PREGNANCY PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; WOUND HEALING;

EID: 19244379078     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/87904     Document Type: Article

References (45)

1. Dvorak, H.F. VPF/VEGF and the angiogenic response. Semin. Perinatol. 24, 75-78 (2000).
2. Ferrara, N. Vascular endothelial growth factor: molecular and biological aspects. Curr. Top. Microbiol. Immunol. 237, 1-30 (1999).
3. Persico, M.G., Vincenti, V. & DiPalma, T. Structure, expression and receptor-binding properties of placenta growth factor (PIGF). Curr. Top. Microbiol. Immunol. 237, 31-40 (1999).
4. Achen, M.G., Gad, J.M., Stacker, S.A. & Wilks, A.F. Placenta growth factor and vascular endothelial growth factor are co-expressed during early embryonic development. Growth Factors 15, 69-80 (1997).
5. Monsky, W.L. et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res. 59, 4129-4135 (1999).
6. Park, I.E., Chen, H.H., Winer, J., Houck, K.A. & Ferrara, N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem. 269, 25646-25654 (1994).
7. Viglietto, G. et al. Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. Oncogene 13, 577-587 (1996).
8. Nomura, M. et al. Placenta growth factor (PIGF) mRNA expression in brain tumors. J. Neurooncol. 40, 123-30 (1998).
9. Neufeld, G., Cohen, T., Gengrinovitch, S. & Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13, 9-22 (1999).
10. Shibuya, M., Ito, N. & Claesson-Welsh, L. Structure and function of vascular endothelial growth factor receptor-1 and -2. Curr. Top. Microbiol. Immunol. 237, 59-83 (1999).
11. Fong, G.H., Rossant, J., Gertsenstein, M. & Breitman, M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66-70 (1995).
12. Hiratsuka, S., Minowa, O., Kuno, J., Noda, T. & Shibuya, M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. USA 95, 9349-9354 (1998).
13. Kendall, R.L., Wang, G. & Thomas, K.A. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun. 226, 324-328 (1996).
14. Clark, D.E. et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol. Reprod. 59, 1540-1548 (1998).
15. Landgren, E., Schiller, P., Cao, Y. & Claesson-Welsh, L. Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-γ and migration of endothelial cells expressing Flt 1. Oncogene 16, 359-367 (1998).
16. Cao, Y., Linden, P., Shima, D., Browne, F. & Folkman, J. In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. J. Clin. Invest 98, 2507-2511 (1996).
17. DiSalvo, J. et al. Purification and characterization of a naturally occurring vascular endothelial growth factor.placenta growth factor heterodimer. J. Biol. Chem. 270, 7717-7723 (1995).
18. Olofsson, B., Jeltsch, M., Eriksson, U. & Alitalo, K. Current biology of VEGF-B and VEGF-C. Curr. Opin. Biotechnol. 10, 528-535 (1999).
19. Aase, K. et al. VEGF-B deficient mice display an atrial conduction defect. Circulation (in the press).
20. Hatva, E. et al. Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. Am. J. Pathol. 148, 763-775 (1996).
21. Takahashi, A. et al. Identification of receptor genes in renal cell carcinoma associated with angiogenesis by differential hybridization technique. Biochem. Biophys. Res. Commun. 257, 855-859 (1999).
22. Viglietto, G. et al. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PIGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11, 1569-1579 (1995).
23. Simpson, D.A. et al. Expression of the VEGF gene family during retinal vaso-obliteration and hypoxia. Biochem. Biophys. Res. Commun. 262, 333-340 (1999).
24. Khaliq, A. et al. Increased expression of placenta growth factor in proliferative diabetic retinopathy. Lab. Invest. 78, 109-116 (1998).
25. Heymans, S. et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nature Med. 5, 1135-1142 (1999).
26. Arras, M. et al. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J. Clin. Invest. 101, 40-50 (1998).
27. Clauss, M. et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J. Biol. Chem. 271, 17629-17634 (1996).
28. Rafii, S. Circulating endothelial precursors: mystery, reality, and promise. J. Clin. Invest. 105, 17-19 (2000).
29. Kalka, C. et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ. Res. 86, 1198-1202 (2000).
30. Eliceiri, B.P. et al. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell. 4, 915-924 (1999).
31. He, H. et al. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J. Biol. Chem. 274, 25130-25135 (1999).
32. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nature Med. 6, 389-395 (2000).
33. Migdal, M. et al. Neuropilin-1 is a placenta growth factor-2 receptor. J. Biol. Chem. 273, 22272-22278 (1998).
34. Gerber, H.P. et al. VEGF is required for growth and survival in neonatal mice. Development 126, 1149-1159 (1999).
35. Carmeliet, P. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439 (1996).
36. Witte, L. et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 17, 155-161 (1998).
37. Carmeliet, P. et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98, 147-157 (1999).
38. Carmeliet, P. et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nature Med. 5, 495-502 (1999).
39. Passaniti, A. et al. A simple, quantitative method for assessing aniogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibrob-last growth factor. Lab. Invest. 67, 519-528 (1992).
40. Carmeliet, P. et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394, 485-490 (1998).
41. Ryan, H.E. et al. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res. 60, 4010-4015 (2000).
42. Frank, S. et al. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J. Biol. Chem. 270, 12607-12613 (1995).
43. Thurston, G. et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nature Med. 6, 460-463 (2000).
44. Vicaut, E. & Stucker, O. An intact cremaster muscle preparation for studying the microcirculation by in vivo microscopy. Mircovasc. Res. 39, 120-122 (1990).
45. Nicosia, R.F. & Villaschi, S. Autoregulation of angiogenesis by cells of the vessel wall. Int. Rev. Cytol. 185, 1-43 (1999).